脑宁康颗粒治疗中风先兆证临床疗效研究

Studies on clinically curative effects of Naoningkang pellet(脑宁康颗粒) on stroke precursor

目的 :观察脑宁康颗粒治疗中风先兆证的临床疗效。方法 :中风先兆证患者 114例 ,随机分为脑宁康治疗组和阿斯匹林治疗对照组。观察 2组给药前后临床积分、血小板膜表面受体 (CD6 2 P)、内皮素 1(ET 1)、红细胞 C3b受体花环率 (RBC C3b RR)、丙二醛 (MDA)等参数的变化。结果 :治疗组总有效率 94.74% ,1年内中风发生率 1.75 % ,给药后治疗组 CD6 2 P、ET 1、RBC C3b RR、MDA分别为 (1.48± 0 .0 4) %、(6 0 .31±2 6 .0 5 ) ng/ L、(11.0 3± 2 .2 4) %和 (1.72± 0 .31) μm ol/ L,较给药前均显著或极显著改善 (P<0 .0 5或 P<0 .0 1) ,以上参数与对照组比较 ,均有显著性差异 (P均 <0 .0 5 )。结论 :脑宁康颗粒不仅能明显改善中风先兆证症状、有效控制中风发生 ,且对患者血管内皮、血小板活化功能、神经免疫调制及抗氧化功能有明显改善 。

Objective:To observe the clinically curative effects of Naoningkang pellet (NNKP, on stroke precursor.Methods:One hundred and fourteen cases with stroke precursor were randomly divided into treatment group which treated with NNKP and control group which treated with Aspirin.The changes in clinical scores,cluster of differentiation 62 P(CD 62P ),endothelin1(ET1),red blood cell C 3b receptor rate (RBCC 3bRR),and malondialdehyde(MDA) were observed before and after therapy.Results:The totally effective rate in treatment group was 94 74%,the occurrance rate of stroke within one year was 1 75% and after therapy the CD 62P ,ET1,RBCC 3bRR,and MDA were(1 48±0 04)%,(60 31± 26 05)ng/L ,( 11 03± 2 24)% and (1 72±0 31) μmol/L respectively in treatment group and in comparison with before therapy all the improvements were significant ( P <0 05 or P <0 01),meanwhile the differences in all the abovementioned parameters in comparison with control group were significant (all P <0 05).Conclusions:NNKP is not only able to improve the symptoms of stroke precursor and control the occurrance of stroke but also to improve the functions of vascular endothelium,platelet activation,neuroimmune regulation,and antioxidation obviously in patients.Its efficacy is markedly better than Aspirin.